9 results
8-K
EX-99.3
IVVD
Invivyd Inc
22 Mar 24
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
8:58pm
high-dose corticosteroids/other immunosuppressive medications 65% 0% Acute leukemia, chronic lymphocytic leukemia, non-Hodgkin, lymphoma, 13% 0 … ] 30 kg/m2) 38% 40% Diabetes (Type 1 or Type 2) 18% 9% Chronic kidney disease 10% 1% Chronic lung disease 18% 3% Cardiac disease 42% 23% Stroke
8-K
EX-99.1
IVVD
Invivyd Inc
7 May 24
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19
7:38am
infection,” said Brian Koffman, MDCM (retired), MS Ed, Co-Founder, Executive Vice President and Chief Medical Officer of the CLL (Chronic Lymphocytic
8-K
EX-99.1
IVVD
Invivyd Inc
11 Sep 23
Other Events
7:10am
it was no longer considered 5 effective.” — Neurologist Multiple sclerosis 5 Psoriasis ” 5 Early-stage chronic kidney disease 1. Participants were asked
PREC14A
IVVD
Invivyd Inc
11 Apr 22
Preliminary proxy with contested solicitation
6:44am
diseases, chronic pain, anxiety and depression, and has served in this position since June 2020. Since November 2021, she has served as Non-Executive … such as stroke and heart disease, diabetes, obesity, lung diseases, chronic pain, anxiety and depression. Dr. Meanwell is also the co-founder of Population
PRRN14A
IVVD
Invivyd Inc
25 Apr 22
Revised preliminary proxy statement filed by non-management
5:23pm
conditions such as stroke and heart disease, diabetes, obesity, lung diseases, chronic pain, anxiety and depression, and has served in this position since … the drivers of common and burdensome health conditions such as stroke and heart disease, diabetes, obesity, lung diseases, chronic pain, anxiety
DEFC14A
ury6jw
29 Apr 22
Proxy in contested solicitation
4:02pm
PRRN14A
g2vud7vo
27 Apr 22
Revised preliminary proxy statement filed by non-management
1:13pm
10-K
malixcp3y biq9crs6no
31 Mar 22
Annual report
8:18am
- Prev
- 1
- Next